NASDAQ$HCAT
Health Catalyst Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Health Catalyst reported strong performance in Q3 2020, exceeding revenue and Adjusted EBITDA guidance.
Health Catalyst reported a 20% increase in total revenue to $47.2 million and an adjusted EBITDA of negative $6.4 million for the third quarter of 2020. The company exceeded the midpoint of its quarterly guidance for both revenue and Adjusted EBITDA.
- Total revenue increased by 20% year-over-year to $47.191 million.
- Technology revenue increased by 32% year-over-year to $27.964 million.
- Professional services revenue increased by 5% year-over-year to $19.227 million.
- Adjusted EBITDA improved by 24% year-over-year to negative $6.434 million.
Headline financials
Revenue & EPS history
Health Catalyst · Revenue · Quarterly
$47.2M
Revenue by segment
Health Catalyst · $47.2M total across 2 segments · Q3 2020
- Technology$28M+32.2%59.3%
- Professional Services$19.2M+5.3%40.7%
Forward guidance
Health Catalyst expects total revenue between $50.5 million and $53.5 million and Adjusted EBITDA between $(7.3) million and $(5.3) million for the fourth quarter of 2020. For the full year 2020, the company expects total revenue between $186.1 million and $189.1 million and Adjusted EBITDA between $(23.9) million and $(21.9) million.
Tailwinds
- Total revenue is expected to be between $50.5 million and $53.5 million for Q4 2020.
- Adjusted EBITDA is expected to be between $(7.3) million and $(5.3) million for Q4 2020.
- Total revenue is expected to be between $186.1 million and $189.1 million for the full year 2020.
- Adjusted EBITDA is expected to be between $(23.9) million and $(21.9) million for the full year 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-3.1%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.0%
Avg return
30 days after
41%
11 / 27 earnings
Positive
+27.3%
Q2 2024
Best reaction
-36.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.9% | -21.7% | +4.6% | |
| Q4 2025 | -26.3% | -35.2% | -44.4% | |
| Q3 2025 | -5.6% | -20.5% | -10.2% | |
| Q1 2025 | +5.3% | +8.1% | +3.3% | |
| Q4 2024 | -11.1% | -8.5% | -7.9% | |
| Q3 2024 | +14.2% | +7.2% | +7.6% | |
| Q2 2024 | +27.3% | +7.3% | +22.9% | |
| Q1 2024 | -3.6% | +2.9% | -2.3% | |
| Q4 2023 | -14.7% | -8.9% | -14.4% | |
| Q3 2023 | +5.1% | -0.4% | +5.3% | |
| Q2 2023 | -8.0% | -5.0% | -12.4% | |
| Q1 2023 | -18.9% | -14.8% | -4.3% | |
| Q4 2022 | +7.3% | +5.8% | -14.8% | |
| Q3 2022 | +16.2% | +42.9% | +59.2% | |
| Q2 2022 | -36.6% | -34.7% | -35.9% | |
| Q1 2022 | -2.6% | +24.6% | +10.5% | |
| Q4 2021 | +1.5% | -7.1% | -3.7% | |
| Q3 2021 | -6.2% | -6.1% | -26.9% | |
| Q2 2021 | +1.5% | -2.3% | -2.8% | |
| Q1 2021 | -2.3% | -8.6% | -2.4% | |
| Q4 2020 | +0.6% | +0.1% | -2.1% | |
| Q3 2020 | -0.2% | -3.5% | +6.2% | |
| Q2 2020 | -7.2% | -10.9% | -3.4% | |
| Q1 2020 | -1.9% | -0.5% | -5.0% | |
| Q4 2019 | +1.3% | -5.8% | -20.1% | |
| Q3 2019 | +1.9% | -0.8% | -1.1% | |
| Q2 2019 | -11.5% | -7.8% | -13.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro